Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Dasan challenges MSD’s Januvia patent
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Sep 30, 2014 08:17:12
Dasan Medichem filed its lawsuit against MSD Korea’s Januvia to invalidate one of the patents on Januvia, sources said on September 28.

MSD Korea has three patents on Januvia. The patent Dasan challenges expires in June 2024. The post-market surveillance study is not required any longer for Januvia and a few pharmaceutical companies such as Chong Kun Dang and Shinpoong are developing their generic version of Januvia.

Generic drug makers are in a hurry to have their generic version approved for marketing although the brand-name drugs still have valid patents. Once the patent-approval linkage system takes effect in 2015, the process of marketing approval will be delayed.

Dasan Medichem’s purpose to challenge the patent is for the production of its generic version. If the other two patents are not challenged, marketing the generic version of Januvia is still risky.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com